

SUPREME COURT OF THE STATE OF NEW YORK
COUNTY OF WESTCHESTER

ALPHAMEDICA, INC.,

Plaintiff,

- against -

MICHAEL K. FAUST,

Defendant.

Index No.: 4687-07

AFFIDAVIT OF ANDREW GALLER

STATE OF NEW YORK)
) s.s:
COUNTY OF WESTCHESTER)

ANDREW GALLER, being duly sworn deposes and says:

1. I am an owner of stock of Plaintiff AlphaMedica, Inc. ("Plaintiff" or "AlphaMedica"), a corporation organized under the laws of the State of Delaware with its principal place of business located at 220 White Plains Road, Tarrytown, New York 10591. I am also presently a member of the Board of Directors and hold the position of corporate Secretary of AlphaMedica.

2. I submit this Affidavit based upon my personal knowledge in support of the application of Plaintiff for a temporary restraining order and preliminary injunction enjoining Defendant Michael K. Faust, and/or those acting in concert with him ("Mr. Faust"), from: (i) representing himself to third parties as the Chief Executive Officer of AlphaMedica and/or other officer of AlphaMedica; (ii) communicating with the clients of AlphaMedica; (iii) revealing or disclosing the confidences or secrets of AlphaMedica to any third parties; (iv) revealing or disclosing materials in any form constituting AlphaMedica confidential business information and AlphaMedica trade secrets to any third parties; and (v) taking any steps, as threatened by him, to

destroy the business relationships of AlphaMedica.

A. Background

3. AlphaMedica is an educational, pharmaceutical marketing company that does business with major pharmaceutical companies, including, for example, Pfizer Inc. and Allergan Inc.

4. In or about 1999, myself, and other shareholders at the time, including, Kelli A. Mooney, Kerri Riccardo and Defendant Mr. Faust entered into a Shareholders' Agreement, entitled Shareholders' Agreement of AlphaMedica. A true and correct copy of the Shareholders' Agreement of AlphaMedica, Inc., as amended (the "Shareholders' Agreement"), is annexed hereto as Exhibit A.

5. Since in or about 1999, AlphaMedica has operated with a Board of Directors comprised of at least three shareholder members, with myself acting as Secretary, Ms. Mooney acting as President, and Mr. Faust acting as Chairman of the Board and Chief Executive Officer.

6. In June 2001, the Shareholders' Agreement was amended to add the following as shareholders of AlphaMedica: (i) Christine Manning; (ii) Michael Kroha; and (iii) William Stroemer. See Exhibit A hereto.

7. Over the past several weeks, Mr. Faust has on multiple occasions informed me and others within AlphaMedica of his desire to resign from AlphaMedica as its Chief Executive Officer and, in this regard, he has expressed his desire for AlphaMedica to repurchase his shares upon such resignation.

8. Consistent with my understanding of my duties as a member of the Board of Directors, I had no choice but to take seriously Mr. Faust's communications that he wanted to resign as Chief Executive Officer of AlphaMedica.

B. Mr. Faust's Resignation as Chief Executive Officer

9. On March 20, 2007, at a duly noticed and convened telephonic meeting of all members of the Board of Directors, myself and Ms. Mooney, constituting a majority of the Board of Directors, voted and resolved to: (i) accept the resignation of Faust as Chief Executive Officer of AlphaMedica, Inc., effective immediately; (ii) consider the appointment of Mr. Faust as a consultant of AlphaMedica during this transitional period; and (iii) seek to engage a valuation firm for the purpose of placing a value on AlphaMedica, Inc.'s common stock to effectuate a fair and equitable repurchase of Mr. Faust's shares pursuant to the Shareholders' Agreement. A true and correct copy of the Minutes of the March 20, 2007 Meeting of the Board of Directors is annexed hereto as Exhibit B.

10. Mr. Faust remains a member of the Board of Directors of AlphaMedica, and continues to receive compensation and benefits from AlphaMedica in a manner or consistent with past practice.

11. Following the March 20, 2007 Board Meeting, Ms. Mooney and I contacted all of our fellow shareholders present at AlphaMedica's principal office to inform them of the Board of Directors' acceptance of Mr. Faust's resignation as Chief Executive Officer of AlphaMedica.

C. Mr. Faust Has Made Representations That He Has Taken Steps To, And Will Destroy AlphaMedica and Certain of its Shareholders

12. Later in the evening following the meeting of the Board of Directors, Ms. Mooney and I, together with Ms. Riccardo and Mr. William R. Stroemer, who had participated in the earlier call following the Board Meeting, telephoned Michael Kroha, the only other shareholder (other than Mr. Faust), in order to inform him of the Board of Directors' acceptance of Mr. Faust's resignation. Mr. Kroha, at the time, was traveling on behalf of AlphaMedica in London, England.

13. During our telephone call with Mr. Kroha, Mr. Faust, who also happened to be traveling with Mr. Kroha, entered the room where Mr. Kroha was participating in the telephone call and wrested the telephone away from Mr. Kroha.

14. Upon wresting the telephone away from Mr. Kroha, Mr. Faust did not provide us with an opportunity to identify all of the participants on the telephone call, and stated to Ms. Mooney via speaker – for all of us to hear – that he was going to take actions to destroy the integrity and reputation of AlphaMedica, as well as the integrity and reputation of certain of its shareholders.

15. Specifically, Mr. Faust threatened that he was going to take any and all steps to destroy AlphaMedica's existing multi-million dollar contracts with Pfizer Inc. and that he had in fact "already taken care of that," i.e., taken steps to destroy or impede AlphaMedica's existing, continued and future relationship with Pfizer, Inc.

16. Mr. Faust also threatened that AlphaMedica's significant multi-million dollar business and goodwill with Allergan Inc. was "next" to be destroyed by him to be destroyed by him and that he intended to take all steps necessary to do so.

17. In addition, Mr. Faust made threats concerning our fellow shareholder, Mr. Stroemer, and stated that Mr. Stroemer would be "dead" and that he intended to take any and all action so that Mr. Stroemer would have "no career left." Mr. Faust also made threats about me, stating that "[I] was dead too."

18. Mr. Faust moreover threatened Ms. Mooney and warned her that because she had apparently voted, as I did, to accept his resignation as Chief Executive Officer of AlphaMedica at the meeting of the Board of Directors, Ms. Mooney had "chosen the wrong partner to team up with."

19. Mr. Faust finally demanded that he be given an apology within twenty minutes after the telephone call "or [he] will tear the company apart" so that "there will be no AlphaMedica left as you know it."

D. Mr. Faust's Has and/or Continues to Take Other Damaging Actions

20. Together with Ms. Mooney and the other shareholders of AlphaMedica, Inc., I learned that Mr. Faust contacted various employees of AlphaMedica after being instructed by a majority of the Board of Directors not to do so.

21. For example, I learned that on March 20, 2007, Mr. Faust contacted Ms. Autumn Chamberlain, an AlphaMedica employee, and directed her to remove the computer utilized by Mr. Faust at AlphaMedica's principal office from the premises and move it into her vehicle. In fact, on March 20, 2007, I observed Ms. Chamberlain re-entering the premises with the computer after having brought it to her vehicle, at which time I spoke with her and reminded her that the computer was property of AlphaMedica, not Mr. Faust.

22. Notwithstanding my discussion with Ms. Chamberlain regarding the computer, I discovered that the computer was missing from the principal office of AlphaMedica later that evening. I believe that Ms. Chamberlain, or someone else acting on behalf of Mr. Faust, is in possession of the computer belonging to AlphaMedica. I have written Mr. Faust and Ms. Chamberlain via e-mail requesting immediate return of AlphaMedica's property. I have not received any response from either Ms. Chamberlain or Mr. Faust. Notably, Ms. Chamberlain did not report to work today.

23. Moreover, despite precautions that we took with regard to AlphaMedica's electronic files and computer system, and despite that Mr. Faust does not need complete access to AlphaMedica's files as a non-officer member of the Board of Directors, Mr. Faust contacted


AlphaMedica's Information Technologies specialist, Timothy Palmer, late in the evening on March 20, 2007 and directed Mr. Palmer to restore all access to AlphaMedica's electronic files. Mr. Palmer complied with Mr. Faust's demands.

24. Mr. Faust's access to AlphaMedica's electronic files has now been limited once again, effective the morning of March 21, 2007, after we learned of Mr. Palmer's actions in response to Mr. Faust's demands; nonetheless, I remain concerned that Mr. Faust is taking measures to destroy and/or alter company files. Indeed, his company computer remains missing since March 20, 2007.

25. To the extent, that Mr. Faust has extracted, intends to extract or has caused someone else to extract confidential business information from AlphaMedica's electronic files and computer, Mr. Faust acted and/or is acting without authority from AlphaMedica, and such information must be returned to AlphaMedica immediately.

26. If AlphaMedica were to lose valuable clients and the goodwill that it has established as a competitive and reliable agency due to the actions taken and/or threatened by Mr. Faust, it would seriously and irreparably damage AlphaMedica's viability.

27. I believe that immediate relief enjoining Mr. Faust is required to preserve AlphaMedica's business and to enforce Mr. Faust's compliance with the duties that he owes AlphaMedica as a member of its Board of Directors and as a shareholder.



Andrew Galler

Sworn to before me this
27th day of March 2007

Caitlin Morrison
 Notary Public

CAITLIN A. MORRISON
 Notary Public, State of New York
 No. 01MO6153739
 Qualified in Queens County
 Commission Expires Oct. 16, 2010

SHAREHOLDERS' AGREEMENT
OF
ALPHAMEDICA, INC.

SHAREHOLDER'S AGREEMENT made as of the 1st day of July, 1999, by and among AlphaMedica, Inc., a Delaware corporation (the "Company"), and those individuals whose names and addresses are set forth on Exhibit A annexed hereto (individually, a "Shareholder" and collectively, the "Shareholders").

Recitals.

1. The Shareholders are the owners of the number of shares of common stock, without par value, of the Company (the "Common Stock"), representing in the aggregate 100 percent (100%) of the issued and outstanding shares of Common Stock of the Company; and

2. The Shareholders desire to set forth their agreement with respect to the matters set forth herein.

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein, the parties hereto agree as follows:

1. Transfer Restrictions.

1.1. General Restrictions. Each Shareholder hereby agrees that, so long as this Agreement shall remain in effect, any Shares (as defined herein), or any interest therein, whether now owned or hereinafter acquired, shall not be offered for sale, sold, assigned, bequeathed, transferred (including by will or pursuant to the laws of descent and distribution or otherwise), pledged, encumbered, or otherwise disposed of, nor made subject to a

security interest therein (in each case, a "Transfer") except in strict compliance with the provisions of this Agreement. The term "Shares" shall be deemed to include the shares of Common Stock of the Company, now or hereafter issued and outstanding, as well as each and every class of equity securities as may now or hereafter be authorized for issuance by the Company.

1.2. Prohibited Transfers. Except as otherwise required by law, any Transfer of Shares in violation of this Agreement shall be null and void. The Company shall not record such Transfer on its books and shall not recognize any equitable or other claim to or any interest in such Shares on the part of any person other than the Shareholder from whom such Shares were Transferred.

1.3. Legends. All certificates representing Shares of the Company shall bear a legend in substantially the following form:

"This certificate and the shares represented hereby may not be offered for sale, sold, bequeathed, transferred (including by will or pursuant to the laws of descent and distribution or otherwise), pledged, encumbered or otherwise disposed of except as provided in a Shareholders' Agreement dated as of July 1, 1999 among the corporation and its shareholders, a copy of which agreement is on file at the office of the corporation. Any purported transfer in violation of such agreement shall be void.

1.4. Transfer Agreements. Each Transfer of Shares by a Shareholder shall be by written agreement, in a form reasonably satisfactory to the Company and its counsel, in which the transferee agrees to hold such Shares subject to, and abide by, all the terms of this Agreement; and counterparts of such agreement, duly executed by the parties thereto, shall be delivered at the consummation of the transfer.

mation of such Transfer to the Company. Whether or not such an agreement is so executed and delivered, the transferee of such shares shall be deemed, by accepting such shares, to have agreed to hold such shares subject to all the terms of this Agreement.

1.5. Transfer of Beneficial Interest. Any Transfer, whether direct or indirect, of the beneficial interest in Shares of the Company without compliance with the terms hereof with respect to the shares involved, shall be deemed a prohibited Transfer of shares and void pursuant to the terms of Section 1.2 hereof.

2. Rights of First Refusal.

2.1. Transfer Notice; Transfer Price. (a) No Transfer of any shares of Common Stock (except by the laws of descent or distribution) shall be permitted on any terms for a period of eighteen (18) months from the date hereof. Thereafter, if, at any time, any Shareholder receives from any individual or entity a bona fide written offer (which such Shareholder desires to accept), to purchase all of the Shares then owned by such Shareholder, or otherwise proposes to effect a Transfer of Shares, then such Shareholder shall give the Company written notice (the "Transfer Notice") of the name and address of the proposed purchaser or other proposed transferee and a copy of such offer or other proposal, containing all of the terms and conditions thereof, including the name and address of the proposed transferee, the number of Shares proposed to be Transferred (the "Offered Shares") and the price per share which has been offered (the "Transfer Price").

(b) A "bona fide offer" means an offer made in writing by a prospective purchaser who is not an affiliate of any Shareholder and which provides for the payment of the purchase price set forth in such offer in cash, cash equivalents or deferred installments thereof, all in United States funds.

2.2. Offer. The Transfer Notice shall be deemed an irrevocable offer (the "Offer") to sell all, but not less than all, of the Offered Shares to the Company at the lower of the Transfer Price per share and the Agreed Value, as defined in Section 3.5.1(b), below, all on the Alternate Terms, as defined below, and otherwise on the terms and conditions set forth in the Transfer Notice. The day on which the Company receives notice of the offer shall be deemed to be the date of such Offer ("the Offer Date").

2.3. Acceptance of the Offer. (a) The Company shall notify the offering Shareholder within thirty (30) days of the Offer Date of its acceptance or rejection of the Offer or of its election to purchase the Shares on the Alternate Terms, as that term is defined in Section 2.3(b), below. If the offering Shareholder does not receive a notice from the Company within such thirty-day period of the Company's desire to purchase all, but not less than all, of the Offered Shares in accordance with the terms of the offer, then the Company shall be deemed to have rejected the Offer, whereupon the offering Shareholder shall proceed in the manner set forth in Section 2.4. If the Offer is accepted, the Offered Shares shall be sold to the Company and the Company shall purchase the offered Shares at the Closing, as described in Section 2.5 below.

(b) "Alternate Terms" shall have the meaning set forth in Section 3.6.2, below.

2.4. Offer to Shareholders.

2.4.1. In the event that the Company rejects the offer, then the offering Shareholder shall transmit a copy of the Transfer Notice to the non-offering Shareholders, which transmission shall be deemed an irrevocable offer to sell all, but not less than all, of the Offered Shares to the non-offering Shareholders pro rata to their then proportionate ownership of the Common Stock upon the same terms previously offered to the Company. The offering Shareholder shall observe the same formalities required to be observed in Section 2.1 in respect of the Offer to the Company.

2.4.2. The Shareholders who receive a Transfer Notice pursuant to this Section 2.4 shall notify the offering Shareholder within thirty (30) days after the Offer Date (for purposes of this Section 2.4, the date the Transfer Notice was received by the non-offering Shareholder) of his acceptance or rejection of the offer of his or her election to purchase the Shares on the Alternate Terms. If the offering Shareholder does not receive a notice within such thirty-day period indicating a desire on the part of the non-offering Shareholders to purchase all, but not less than all, of the Offered Shares in accordance with the preceding sentence, then the Offer shall be deemed to have been rejected, and the offering Shareholder may Transfer the Offered Shares upon the terms set forth in the Transfer Notice subject to the provisions of the last sentence of this Section 2.4.2. If the Offer is accepted,

the Offered Shares shall be sold to the non-offering Shareholders and the non-offering Shareholders shall purchase the offered Shares at the Closing as described in Section 2.5 below. Any Transfer pursuant to the terms hereof shall be subject to the following restrictions: (a) the Shares being Transferred shall be released solely for the purpose of the proposed sale to the proposed transferee, at the Offering Price, and on the terms specified in the Transfer Notice or on the Alternate Terms, as the case may be; (b) the sale shall occur no later than one hundred and eighty (180) days from the Offer Date to the Company, (c) the transferee shall sign a copy of this Agreement, and (d) if the Company is an S Corporation under the Internal Revenue Code of 1986, as subsequently amended, the transferee shall be an eligible holder of S Corporation stock.

2.5. Closing for Share Purchases. The closing of the purchase of the Offered Shares to be purchased by the Company or a shareholder(s), as the case may be, shall take place within thirty (30) days after the giving of the notice of desire to purchase specified in Sections 2.3 or 2.4. At the closing, the offering shareholder shall sell, convey, transfer and deliver to the purchaser full right, title and interest in and to the Offered Shares, free and clear of all liens, security interests or adverse claims of any kind and nature, and shall deliver to the purchaser of the offered Shares a certificate or certificates representing such Shares, in each case duly endorsed for transfer or accompanied by appropriate stock transfer powers duly endorsed, with signatures

guaranteed in the customary fashion, and with all necessary transfer tax stamps affixed thereto at the expense of the offering Shareholder. Each purchaser of offered Shares shall deliver to the offering Shareholder in full payment of the purchase price for the Shares purchased by it or him such consideration as is required and described in the Transfer Notice, payable on the terms set forth therein.

3. Mandatory Purchases and Sales.

3.1. Corporation's Obligation to Purchase Shares.

3.1.1. Termination Events. Upon the occurrence of any of the following events (each of which is hereinafter called a Termination Event) with respect to any Shareholder, the Corporation (or its Designees) shall purchase, and the Shareholder (or its estate or legal representative) shall sell to the Corporation (or its designees), all of the Shares owned by that Shareholder:

- (a) the death of the Shareholder;
- (b) the adjudication of the Shareholder as insolvent or bankrupt or any other act taken by the Shareholder which could reasonably have the foregoing result;
- (c) the resignation or discharge from employment with the Company of the Shareholder for any reason other than those set forth in Sections 3.1.1(a), (b) and (d) herein; and
- (d) the Permanent Disability (as defined below) of the Shareholder or his or her retirement at the age of 70.

3.1.2. Permanent Disability. Permanent Disability shall mean any mental or physical illness or condition rendering a shareholder incapable of performing his or her normal duties with the Company, notwithstanding any reasonable accommodation which may

be offered to him or her by the Company, for a continuous period of four (4) months or for a period of five (5) months in the aggregate during any continuous twelve (12) month period of the term hereof.

3.1.3. Terms and Conditions of Sales. Any purchase of Shares pursuant to this Section 3.1 shall be subject to the terms and conditions set forth below in Sections 3.2 through 3.7.

3.1.4. Limitation on Obligation. Nothing in this Section 3.1 shall be deemed to permit the Company (or its designees) to purchase Shares hereunder if an option to purchase Shares pursuant to a right of first refusal granted by Section 2 herein is pending.

3.2. Notice of Purchase.

3.2.1. Sending of Notice. If a Termination Event occurs, the Company shall send a notice of purchase (hereinafter called the "Notice of Purchase") with respect to all of the Shares owned by the Shareholder who is the subject of such Event, such Notice to be sent to the subject Shareholder (which term shall include his legal representatives in the event of his death or disability). The Notice of Purchase shall be given within ninety (90) days from and after the date on which the Company acquires actual knowledge of a Termination Event.

3.2.2. Content of Notice. The Notice of Purchase shall specify: (a) that the Company (or its Designee) will purchase all of the Shares owned by the Shareholder; (b) the purchase price per Share (as determined in accordance with the Section 3.5) of any Shares to be purchased and the amount to be paid by each purchaser

of Shares; and (c) the date or dates on which the closing of such purchase is to be held (the "Closing"), which date or dates shall be not more than thirty (30) days after the date on which the Notice of Purchase is given.

3.3. Designation of Purchasers. Whenever the Company shall be required to purchase any Shares pursuant to Section 3.1, the Company may designate such person or persons as a purchaser or purchasers of all or any part of such Shares as it may desire. If any person so designated shall default in his obligation to deliver payment for shares as required by this Agreement or shall default in his obligations under any promissory note given in payment for shares purchased by him, the Company may either designate another purchaser or may pay the purchase price for the Shares in his stead.

3.4. Status of Shares Purchased. In the event of a purchase of Shares pursuant to Section 3.1, then, regardless of when the purchase price of the Shares is paid, (a) all rights of the shareholder from whom such Shares are to be purchased as a holder thereof, other than the right to receive payment of the purchase price of such Shares at the time and place and in the amount and form (whether in cash, evidences of indebtedness, or both) determined as provided in this Agreement, shall be deemed to have terminated as of the day of the Termination Event (the "Termination Date"); and (b) such Shares shall be deemed to be no longer outstanding for any purpose, or, if purchased by a purchaser or purchasers other than the Company, shall be deemed to be owned by

such purchaser or purchasers for all purposes, from and after the Termination Date. Each of the Shareholders hereby agrees that, as to the Shares sold, from and after the Termination Date, the Shareholder whose Shares have been sold shall have no interest in the profits, losses, or income of the Company, whether or not such profits, losses or income are in respect of events occurring prior to the Termination Date, and no right to participate in the Company's affairs.

3.5. Purchase Price.

3.5.1. (a) The purchase price for any shares to be purchased pursuant to the provisions of Section 3.1.1(a) shall be equal to 100% of Agreed Value, as hereafter defined, of such Shares. The purchase price for any shares to be purchased pursuant to the provisions of Sections 3.1.1(b) and (c) shall be equal to seventy-five percent (75%) of Book Value, as hereafter defined, of such shares. The purchase price for any shares purchased pursuant to the provisions of Section 3.1.1(d) shall be equal to one hundred percent (100%) of Book Value, as hereafter defined, of such shares. If the conditions set forth in Section 3.5.2 have been met, the applicable price shall be calculated in accordance with the terms thereof.

(b) Agreed Value shall mean the value of the shares of stock of the Company which is fixed by a certificate of agreed value (the "Certificate") signed by each of Todd Retallack, Kelli Mooney, Andrew Galler and Michael Faust (the "Deciding Shareholders") and filed with the Company not less than annually,

commencing on the effective date of this Agreement. The Agreed value set forth in such certificate shall be reasonable in light of the then circumstances, financial and otherwise, of the Company and shall be conclusive as to the value of the stock for purposes of this Section 3.5.1. In no event shall a Certificate be effective unless signed by all of the Deciding Shareholders. The Deciding Shareholders may at any time execute a new Certificate which shall automatically replace all prior Certificates, and in no event shall any but the last Certificate be effective for the purposes herein specified. No Certificate, however, shall be effective for any purpose if it was executed more than twelve (12) months before the date for the determination of Agreed value occasioned by the occurrence of any of the events set forth in Sections 3.1.1(a)-(d) hereof.

3.5.2 (a) If a Certificate has not been prepared in accordance with the requirements of Section 3.5.1(b), the purchase price for the Shares shall be as follows:

(i) if the obligation arises under Section 3.1.1(a), the purchase price shall be equal to 100% of the Book Value of such Shareholder's Shares, calculated as at the end of the Company's fiscal quarter next preceding the date of the Termination Event by the Company's regularly employed accountants in a manner consistent with the methods used by such accountants in preparing the Company's audited or reviewed financial statements for the Company's fiscal year next preceding the date of the Termination Event (as so calculated, the "Book Value");

(ii) if the obligation arises under Sections 3.1.1(b) or (c), the purchase price shall be equal to 70% of the Book Value; (iii) if the obligation arises under Sections 3.1 (d), the purchase price shall be equal to 100% of the Book Value of the Shares.

(b) In addition to payment for his shares, a Shareholder who is under a Permanent Disability shall be entitled to receive: (x) as salary continuation, his full compensation in effect at the date of the Termination Event from that date until the earlier of the date of the first payment to the applicable shareholder pursuant to any policy of disability insurance maintained for the benefit of such Shareholder by the Company (the "Disability Payment Date") or the date 60 days after the Termination Event, such amount payable as had regularly been paid to the disabled Shareholder prior to the date of the Termination Event; (y) as additional salary continuation, an amount equal to the difference between the total compensation paid by the Company to the remaining Shareholder during the period commencing on the Disability Payment Date and ending on the date twelve months thereafter and twice the amount paid (or, if the Disability Policy is not then in force, the amount that would have been paid pursuant to the terms thereof) to the disabled Shareholder pursuant to the Disability Policy during the same period, such amount payable monthly commencing on the Disability Payment Date; and (z) as a severance payment, an amount equal to the Company's net profits during each of the seven fiscal years following the date of the

Termination Event multiplied by the product of 5% and a fraction, the numerator of which is the number of Shares owned by the disabled Shareholder and purchased pursuant to the provisions hereof and the denominator of which is the then total number of issued and outstanding Shares of the Company; said net profits to be calculated before distribution for any compensation paid to the remaining Shareholders and otherwise in accordance with the Company's audited or reviewed financial statements for each of such fiscal years, and payable within 60 days after the end of each such fiscal year.

3.6. Payment of Purchase Price. The terms of payment for any Shares purchased pursuant to this Section 3 shall be the following:

3.6.1 (a) the Purchaser shall deliver to the selling Shareholder or his legal representative in full payment of the purchase price for the Shares purchased a certified check payable to the order of the selling Shareholder or his representative in an amount equal to ten percent (10%) of the total purchase price as determined pursuant to Section 3.5 above and shall deliver in payment of the balance thereof a promissory note payable in equal quarterly installments over ten years including interest thereon at the rate set by the Commissioner of the Internal Revenue Service for the computation of imputed interest. Payment of amounts due under such note shall be secured by a pledge of the stock so purchased in form and terms reasonably satisfactory to the selling Shareholder or his representative. The payment terms set forth herein are collectively referred to as the "Alternate Terms".

(b) Nothing contained in this Section 3.6 shall be construed to prevent the Company (or its designees) from paying any of the consideration for the purchase of Shares in a manner not provided for herein, if mutually agreed to in writing by the Purchaser and the Shareholder from whom such Shares are to be purchased.

3.7. Delivery of Certificates. Certificates evidencing all Shares which are being purchased pursuant to Section 3.1 shall be delivered to the Company at its principal office and the Company shall maintain temporary custody of Shares for any purchaser other than the Company, at the time of the first payment due hereunder, such certificates to be free and clear of all liens, security interests or adverse claims of any kind and nature, duly endorsed for transfer or accompanied by one or more duly executed stock powers, and with all stock transfer taxes paid or provided for by the seller.

4. Operation of the Company; Voting of Shares. (a) During the term hereof, each Shareholder agrees to vote the shares owned by him (i) to maintain the number of directors constituting the entire Board of Directors at four (4) persons, and (ii) in favor of the election of each of the Deciding Shareholders as directors of the Company. Each Shareholder agrees to cause the following persons to be elected to offices set forth opposite his or her name:

<u>Name</u>	<u>Offices</u>
Michael Faust	Chairman and Managing Director
Todd Retallack	President and Managing Director

Kelli Mooney	Vice President
Andrew Galler	Secretary
Michael Faust	Treasurer

Each of the Shareholders shall be entitled to receive the salary and other benefits to the extent determined by the Board of Directors of the Company.

(b) For so long as this Agreement is in effect, if any Shareholder fails or refuses to vote his Stock as provided in this Agreement, without further action by that Shareholder, the other Shareholders, jointly and severally, shall have an irrevocable proxy to vote in accordance with this Agreement all the Shares of the failing or refusing Shareholder and each Shareholder hereby grants to the other Shareholders such irrevocable proxy, which each Shareholder agrees is coupled with an interest.

5. Investment Representations. Each Shareholder represents that he acquired Shares for investment and not for resale or distribution to others, but solely for such Shareholder's own account and each Shareholder agrees that he will not sell or otherwise distribute such Shares or any interest therein, unless they are registered under the Securities Act of 1933 and any applicable state securities laws, unless an exemption from such federal and state laws is available. Each Shareholder agrees that he will not transfer Shares unless the transferee thereof executes and delivers to the Company an investment representation letter, executed by such transferee, containing representations substantially similar to those set forth in this Section 5.

6. Non-Competition; Non-Solicitation; Confidentiality. (a) Each Shareholder agrees that for so long as he owns shares of the Company or is employed thereby and for 12 months after the later of (i) the date on which he ceases to be a Shareholder and (ii) the date on which he ceases to be an employee, he will not directly or indirectly own, operate, join, control, engage in, or participate in the ownership, management, operation or control of, or be a director or an employee of, or a business consultant to, any business, firm, or corporation the business of which is similar to or competes with the business of the Company or any of its Affiliates as conducted during the term of such Shareholder's employment; provided, however, that the provisions of this section shall not apply to investments by a Shareholder in shares of stock traded on a national securities exchange or over-the-counter market which shall have an aggregate market value, at the time of acquisition, of less than \$50,000 and which shall constitute less than one percent of the outstanding shares of such stock.

(b) Each Shareholder agrees that in the event of the termination of his employment with the Company or any Affiliate thereof for any reason or the sale of his or her Shares, such Shareholder shall not, prior to the third anniversary of the last to occur of his termination of employment or sale of his shares, directly or indirectly, (i) solicit any client of the Company or any Affiliate at the time of such Shareholder's termination or during the six months prior thereto; or (ii) render services which are within the scope of the Company's or any Affiliate's business to any such

client as an employee, consultant, director, officer or agent of a competitor of the Company or any Affiliate; or (iii) solicit for purposes of employment any employee of the Company or any of its Affiliates, or induce any such employee to terminate such employee's employment with the Company or any Affiliate.

(c) Each Shareholder agrees that both during his or her employment and after termination thereof, each Shareholder will not do any act which is intentionally detrimental to the reputation of the Company or any of its Affiliates, such as making derogatory or disparaging remarks about the Company or its Affiliates or their employees; and each Shareholder will not reveal or use confidential or proprietary information about the Company, or any of its Affiliates or its clients obtained by the holder while an employee.

(d) Any breach or threatened breach of any of the covenants in this Section 6 will cause irreparable injury and incalculable damage to the Company or an Affiliate thereof and the Company and any such Affiliate shall accordingly be entitled to apply for and obtain injunctive relief for the same in any court of competent jurisdiction in addition to all other remedies which might be available to it or them and each Shareholder agrees not to raise in any such action the defense that plaintiff may have an adequate remedy at law.

(e) "Affiliate" shall mean any partnership, corporation, association, trust, unincorporated organization or other entity ("Entity") that directly or indirectly controls, is controlled by or is under common control with an Entity. As used in the definition

of "Affiliate," the term "control" means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an Entity, whether through ownership of voting securities, by contract or otherwise. The term "control" for purposes of a joint venture means the possession by an Entity of the ownership of securities constituting more than twenty-five (25%) of the outstanding voting securities or equity interests of the joint venture and a determination by the Company that the Entity's interest therein is sufficient to be deemed control.

7. General

7.1. No Waiver, Remedies Cumulative. No action taken by any party hereto shall be deemed to constitute a waiver by such party of compliance with any covenant or agreement contained in this Agreement. No course of dealing between the parties hereto and no failure or delay on the part of any party hereto in exercising any right, power, or privilege hereunder shall operate as a waiver thereof; and no single or partial exercise of any right, power or privilege shall preclude any other or future exercise thereof or the exercise of any other right, power or privilege. The rights and remedies provided herein are cumulative and not exclusive of any right or remedies which the parties would otherwise have. The waiver of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.

7.2. Entire Agreement, Amendments, Termination. (a) This Agreement constitutes the entire agreement, and supersedes all prior agreements and understandings, oral and written, between the parties

hereto with respect to the subject matter hereof. No modification, amendment or waiver of any provision of this Agreement shall be effective unless in writing and signed by the parties against whom enforcement thereof is sought; and any such waiver or consent shall be effective only in the specific instance and for the purpose for which given.

(b) This Agreement shall terminate on its tenth anniversary and shall terminate earlier upon the effectiveness of a registration statement filed by the Company pursuant to the Securities Act of 1933, as amended, and the sale of common stock or other equity securities of the Company pursuant thereto.

7.3. Specific Performance. The parties hereto acknowledge that the Shares are unique and that there may be no adequate remedy at law for that failure of any party to perform his obligations hereunder with respect to such Shares. In the event of such failure, any party hereto shall have the right, in addition to any other rights such party may have, at law, in equity or otherwise, to specific performance of any and all such other party's obligations under this Agreement.

7.4. Notices. Except as otherwise specified herein, all notices, requests, demands, consents, exercises of options, and other communications required or permitted to be given or made under this Agreement shall be in writing and shall be deemed to have been duly given or made when received, either hand delivered, telexed or mailed, express, registered or certified first class mail, postage

prepaid, return receipt requested, to the party to whom the same is so given or made.

7.4.1. If to the Company, to:

AlphaMedica, Inc.
Shadowbrook
821 North Broadway
Irvington, New York 10533

With a copy to:

Pirro, Collier, Cohen & Halpern, LLP
One North Lexington Avenue
White Plains, New York 10601
Attention: David A. Newberg, Esq.

7.4.2. If to any Shareholder:

The address listed on Schedule A

7.4.3. If to any party, to such other address as such party shall have specified by notice to the other parties.

7.5. Binding Effect: Benefits. This Agreement shall be binding upon and shall inure to the benefit of and be enforceable by the parties hereto and their respective successors, assigns, heirs and legal representatives.

7.6. Separability. The invalidity of all or any part of any Section of this Agreement shall not render invalid the remainder of such Section or of this Agreement. If any provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable.

7.7. Headings. The headings of this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.


7.8. Execution in Counterparts. This Agreement may be executed in any number of counterparts, each of which shall, when executed, be deemed to be an original and all of which shall be deemed to be one and the same instrument.

7.9. Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed and interpreted in all respects in accordance with, the laws of the State of Delaware.


7.10. Subchapter S Status. The parties acknowledge that the Company has elected to be taxed for Federal and state income tax purposes in accordance with Subchapter S of the Internal Revenue Code of 1986, as amended (the "Election"). In furtherance thereof, the parties agree that, in the event the consummation of any of the transactions contemplated by any provision of this Agreement would, in the opinion of counsel to the Company or any Shareholder, have the effect of terminating the Election, such transaction shall not be consummated without the written consent of the parties hereto, who shall use their best efforts to take whatever actions may be necessary to preserve the Election and to give effect to the economic effect of the transaction then at issue.


IN WITNESS WHEREOF, the undersigned have executed this Agreement or caused this Agreement to be executed on their behalf as of the date first above written.

ALPHAMEDICA, INC.

By: 
Title: Chairman



Todd Retallack


Kelli Mooney

Andrew Galler


Michael Faust


Vincent Tozzi


Kerri Riccardo


Andrew Minkinger
AKA




EXHIBIT A

<u>SHAREHOLDER NAME AND ADDRESS</u>	<u>NUMBER OF SHARES</u>
Todd Retallack 213 South Broadway Nyack, NY 10960	500
Kelli Moonay 116 Seacord Road New Rochelle, NY 10804	500
Andrew Galler 100 Travis Corners Road Garrison, NY 10524	500
Michael Faust 12 Ivy Place Upper Saddle River, NJ 07458	500
Vincent Tozzi Shadowbrook 821 North Broadway Irvington, New York 10533	115
Kerri Riccardo 24 Hubbell Place Milford, Connecticut 06460	115
Andrew Mininger 333 East 69th Street, Apt. 4G New York, New York 10021	57.5

Unanimous Written Consent of
the Shareholders of
AlphaMedica, Inc.


The undersigned, being all of the Shareholders of AlphaMedica, Inc., a Delaware corporation, hereby consent, pursuant to Section 228(a) of the Delaware Corporations Law, to the taking of the actions described in the resolutions set forth below, and such resolutions shall constitute resolutions and actions duly adopted and taken by the Shareholders, without a meeting, as of June 30, 2001:


1. RESOLVED, that the Amendment to Shareholders' Agreement of AlphaMedica, Inc. attached hereto as Exhibit A is approved in all respects.
2. RESOLVED, that the Shareholders will take any and all steps and execute and deliver the Amendment and any and all instruments necessary or desirable to effectuate the foregoing resolution.


Shareholders of AlphaMedica, Inc.


Kelli Mooney


Andrew Galler


Michael Faust


Kerril Riccardo


Christine Manning


Michael Kroha


William Stroebe



Vincent Topzi

EXHIBIT A

AMENDMENT TO SHAREHOLDERS' AGREEMENT OF
ALPHAMEDICA, INC.

This AMENDMENT TO SHAREHOLDERS' AGREEMENT OF ALPHAMEDICA, INC. is made and entered into as of the 30th day of June 2001 by the undersigned.

The parties hereby agree that Exhibit A of the Shareholders' Agreement of AlphaMedica, Inc. dated as of July 1, 1999 (the "Agreement") is hereby amended in its entirety to be the Exhibit A attached hereto and made a part hereof.


All other terms of the Agreement not inconsistent with this Amendment to Shareholders' Agreement shall remain in full force and effect.


IN WITNESS WHEREOF, the parties hereto have caused this Amendment to Shareholders' Agreement of AlphaMedica, Inc. to be executed as of the day and year first above written.

ALPHAMEDICA, INC.


By: 


Authorized Signatory



Kelli Mooney

Andrew Galler 


Michael Faust


Kent Riccardo


Christine Manning


Michael Kroha


William Stroemer


Vincent Tozzi

EXHIBIT A

<u>SHAREHOLDER NAME AND ADDRESS</u>	<u>NUMBER OF SHARES</u>
Kelli Mooney 116 Seascord Road New Rochelle, New York 10804	594,7494
Andrew Galler 100 Travis Corners Road Garrison, New York 10524	594,7494
Michael Faust 12 Ivy Place Upper Saddle River, New Jersey 07458	594,7494
Kerri Riccardo 24 Hubbell Place Milford, Connecticut 06460	183
Christine Manning 257 Country Club Drive Oradell, New Jersey 07649	183
Michael Kroha c/o AlphaMedica, Inc. 220 White Plains Road, 4 th Floor Tarrytown, New York 10591	45.75
William Stroemer c/o AlphaMedica, Inc. 220 White Plains Road, 4 th Floor Tarrytown, New York 10591	45.75
Vincent Tozzi 253 Elizabeth Street, Apartment 6 New York, New York 10012	45.75

Exhibit B

MINUTES OF A SPECIAL MEETING OF
THE BOARD OF DIRECTORS OF
ALPHAMEDICA, INC.

Date: March 20, 2007

Time: 1:00 PM New York time

Directors Present: Andrew Galler
 Kelli Mooney
 Michael Faust

Mr. Andrew Galler called the meeting to order at 1:00 PM New York time announced that a quorum of the Board of Directors (the “Board”) of AlphaMedica Inc., a Delaware corporation (the “Company”) was present and that the meeting, having been duly noticed and convened, was ready to proceed with its business. Mr. Andrew Galler acted as chairman of the meeting and Ms. Kelli Mooney acted as secretary of the meeting.

1. Resignation of Chief Executive Officer.

Next, Mr. Andrew Galler and Ms. Kelli Mooney announced that the Board of Directors had decided to accept the resignation of Mr. Michael Faust as the Company’s CEO and Chairman of the Board of Directors and discussed the possibility of making Mr. Faust a consultant for purposes of providing transition services to the Company while the Company searches for a new Chief Executive Officer. Mr. Galler and Ms. Mooney proposed a consulting fee equal to Mr. Faust’s current salary. A heated discussion ensued and no resolution was reached with respect to the potential consultancy. After discussion, a majority of the Board of Directors approved the following resolution:

RESOLVED that the resignation of Mr. Michael Faust as the Company’s CEO and Chairman of the Board of Directors be, and he hereby is, accepted effective immediately and the Board of Directors shall consider a possible consulting arrangement with Mr. Faust for purposes of providing transition services to the Company following his departure.

2. Retention of Financial Advisory Firm.

Next, Mr. Andrew Galler and Ms. Kelli Mooney announced that the Board of Directors would interview several financial advisory firms for the purposes of conducting a valuation of the Company so that the Company can determine a price at which to repurchase Mr. Faust’s common stock. Mr. Faust stated that he had commissioned an unnamed firm to conduct a valuation and Mr. Galler and Ms. Mooney objected since Mr. Faust did not have the authorization of the Board of Directors to engage any valuation firm. After discussion, a majority of the Board of Director approved the following resolution:

RESOLVED that the Company interview at least three independent valuation firms in the New York metro area and seek to engage one valuation firm for the purpose of placing a value on the Company's common stock.


3. Notice of Board Meeting: Adjournment.

Next, Mr. Galler, Ms. Mooney and Mr. Faust agreed that the Board would meet at a date and time to be agreed upon during the week of March 26, 2007 to discuss transition related matters. There being no further business to come before the Board, on a motion duly made, seconded and unanimously carried, the meeting was adjourned.

APPROVED:

Mr. Andrew Galler, Director


Kelli Mooney, Secretary of the Meeting


Ms. Kelli Mooney, Director

Mr. Michael Faust, Director